SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
JAZZ

Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

IE · Delayed Price · Currency is USD
Healthcare · Biotechnology
$230.26-$6.19 (-2.62%)
 
Market cap
$14.8B
Insider Score
Health Score
Analyst consensus
Listed since
Jun 1, 2007
Market Cap$14.78B+27.3%
Revenue (ttm)$4.72B+13.5%
Net Income$205.95M+155.9%
EPS$3.07+150.6%
Shares Out64.19M
PE Ratio64.32
Forward PE8.58
Dividendn/a
Ex-Dividend Daten/a
Volume984,697
Open$233.99
Previous Close$236.45
Day's Range$227.95 - $238.10
52-Week Range$156.95 - $266.38
Beta0.32
AnalystsBuy
Price Target$295.73(+28.43%)
Earnings DateFeb 23, 2027

About JAZZ

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Address
Waterloo Exchange, Dublin, DU, D04 E5W7, IE
Market Cap
14.78 billion
Employees
2,890
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$22.21M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
9 Buy0 Hold0 SellAvg target $266.91 (+7.7%)

9 firms rating JAZZ in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Sound
From JAZZ’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-2.62%
5 Days
-5.36%
1 Month
+7.27%
6 Months
-3.99%
1 Year
+27.29%

$JAZZ stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of JAZZ by members of U.S. Congress

Thomas SuozziHouse / DSale$1.00K – $15.00KSep 26, 2022
Thomas SuozziHouse / DPurchase$1.00K – $15.00KOct 19, 2021

Recently reported changes in JAZZ holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by JAZZ's directors and management

Net Shares Purchased by Insiders−90k−45k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

JAZZ Estimated quarterly lobbying spending

Source: U.S. Senate LDA

JAZZ Revenue by Segment or Geography

$2.78BTotal
Product sales, net$1.20B42.99%
Sleep$514.00M18.47%
Oncology$387.10M13.91%
Epilepsy$295.40M10.61%
Epidiolex/Epidyolex$295.40M10.61%
All other$48.60M1.75%
High-sodium oxybate AG royalty revenue$38.40M1.38%
Other royalty and contract revenues$8.10M0.29%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New JAZZ patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to JAZZ from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in JAZZ

IJHiShares Core S&P Mid-Cap ETF$538.57M
VTIVanguard Morningstar Total Stock Market ETF$333.06M
VBVanguard Morningstar Small-Cap ETF$298.63M
AFTYPacer CSOP FTSE China A50 ETF$270.47M
VBRVanguard Morningstar Small-Cap Value ETF$194.10M
VFLOVictoryShares Free Cash Flow ETF$172.07M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from JAZZ’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
45

News check: Mixed coverage with valuation concerns offsetting some operational interest; mostly opinion pieces rather than concrete business news.

Recent Insider Activity

Buys
0
Sells
13
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-38.0 since Aug 21
0255075100Aug 21 — Insider Score 38.0Aug 22 — Insider Score 38.0Aug 23 — Insider Score 38.0Aug 24 — Insider Score 38.0Aug 25 — Insider Score 38.0Aug 26 — Insider Score 38.0Aug 27 — Insider Score 39.0Aug 28 — Insider Score 40.0Aug 29 — Insider Score 40.0Aug 30 — Insider Score 40.0Aug 31 — Insider Score 40.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 25.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

HMMJ.TOGlobal X Marijuana Life Sciences Index ETF10.26%
HMLSFGlobal X Marijuana Life Sciences Index ETF10.26%
BTALAGF U.S. Market Neutral Anti-Beta Fund3.72%
PINKSimplify Health Care ETF3.63%
IHEiShares U.S. Pharmaceuticals ETF3.26%
PJPInvesco Pharmaceuticals ETF2.87%
TYNEDirexion Nanotechnology ETF2.79%
MCOWPacer Funds Trust - Pacer S&P MidCap 400 Quality FCF Aristocrats ETF2.75%
ASDDefiance Autism Impact ETF2.66%
XMMOInvesco S&P MidCap Momentum ETF2.57%
FTXHFirst Trust Nasdaq Pharmaceuticals ETF2.57%
SILXETFMG Prime 2x Daily Junior Silver Miners ETF2.31%

Weight is the stock’s share of each fund’s holdings.